Market Overview:
The global osteoporosis drugs market grew at a CAGR of around 5% during 2015-2020. Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.
The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years. Looking forward, IMARC Group expects the global osteoporosis drugs market to exhibit moderate growth during the next five years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product type and route of administration.
Breakup by Product Type:
- Bisphosphonates
- Calcitonin
- Rank Ligand Inhibitor
- Parathyroid Hormone Therapy (PTH)
- Selective Estrogen Receptor Modulators (SERMs)
- Sclerostin Inhibitor
- Others
Breakup by Route of Administration:
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.
Key Questions Answered in This Report:
- How has the global osteoporosis drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global osteoporosis drugs market?
- What are the key regional markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the route of administration?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global osteoporosis drugs market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Osteoporosis Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Bisphosphonates
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Calcitonin
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Rank Ligand Inhibitor
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Parathyroid Hormone Therapy (PTH)
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Selective Estrogen Receptor Modulators (SERMs)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Sclerostin Inhibitor
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Route of Administration
7.1 Oral
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Injectable
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.2 Market Forecast
8.5 Middle East and Africa
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Amgen Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Eli Lilly and Company
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 F. Hoffmann-La Roche AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 SWOT Analysis
13.3.4 GlaxoSmithKline Plc
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Merck & Co. Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 Novartis AG
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Pfizer Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Radius Health Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.9 Teva Pharmaceutical Industries Ltd.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 UCB S.A.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
List of Figures
Table 1: Global: Osteoporosis Drugs (Bisphosphonates) Market: Sales Value (in Million US$), 2015-2020
Table 2: Global: Osteoporosis Drugs (Bisphosphonates) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 3: Global: Osteoporosis Drugs (Calcitonin) Market: Sales Value (in Million US$), 2015-2020
Table 4: Global: Osteoporosis Drugs (Calcitonin) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 5: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market: Sales Value (in Million US$), 2015-2020
Table 6: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 7: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market: Sales Value (in Million US$), 2015-2020
Table 8: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 9: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market: Sales Value (in Million US$), 2015-2020
Table 10: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 11: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market: Sales Value (in Million US$), 2015-2020
Table 12: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 13: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2015-2020
Table 14: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 15: Global: Osteoporosis Drugs (Oral) Market: Sales Value (in Million US$), 2015-2020
Table 16: Global: Osteoporosis Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 17: Global: Osteoporosis Drugs (Injectable) Market: Sales Value (in Million US$), 2015-2020
Table 18: Global: Osteoporosis Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 19: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2015-2020
Table 20: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Table 21: Asia-Pacific: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 22: Asia-Pacific: Osteoporosis Drugs Market: Breakup by Country (in %), 2020
Table 23: China: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 24: China: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 25: Japan: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 26: Japan: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 27: India: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 28: India: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 29: South Korea: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 30: South Korea: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 31: Australia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 32: Australia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 33: Indonesia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 34: Indonesia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 35: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 36: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 37: Europe: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 38: Europe: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 39: Europe: Osteoporosis Drugs Market: Breakup by Country (in %), 2020
Table 40: Germany: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 41: Germany: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 42: France: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 43: France: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 44: United Kingdom: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 45: United Kingdom: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 46: Italy: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 47: Italy: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 48: Spain: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 49: Spain: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 50: Russia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 51: Russia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 52: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 53: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 54: Latin America: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 55: Latin America: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 56: Latin America: Osteoporosis Drugs Market: Breakup by Country (in %), 2020
Table 57: Brazil: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 58: Brazil: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 59: Mexico: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 60: Mexico: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 61: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 62: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 63: Middle East and Africa: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015-2020
Table 64: Middle East and Africa: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Table 65: Middle East and Africa: Osteoporosis Drugs Market: Breakup by Country (in %), 2020
Table 66: Global: Osteoporosis Drugs Industry: SWOT Analysis
Table 67: Global: Osteoporosis Drugs Industry: Value Chain Analysis
Table 68: Global: Osteoporosis Drugs Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Osteoporosis Drugs Market: Key Industry Highlights, 2021 and 2026
Table 2: Global: Osteoporosis Drugs Market Forecast: Breakup by Product Type (in Million US$), 2021-2026
Table 3: Global: Osteoporosis Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
Table 4: Global: Osteoporosis Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 5: Global: Osteoporosis Drugs Market: Competitive Structure
Table 6: Global: Osteoporosis Drugs Market: Key Players